In patients with NSCLC, anti-TIGIT mAb Tiragolumab (Genentech) in combination with anti-PD-L1 mAbs Atezolizumab (Roche) demonstrated prolonged survival in a phase II clinical trial (25). The gene discussed is CD274; the disease is non-small cell lung carcinoma.